APPENDIX II – Eligibility evaluation form

Eligibility evaluation form

Name of reviewer :

Date :

Study ID (first author, journal, year) :

Notes:

For any question regarding the eligibility evaluation, please contact Marie-Claude Laliberté at (514) 343-6111 ext. 1-2598

FOR EACH STUDY, PLEASE ANSWER ALL THE QUESTIONS EVEN IF A STUDY IS EXCLUDED.

INTERVENTION

1. Is this study assessing an **intervention aiming at improving the detection and/or treatment of osteoporosis** (e.g. educational lectures, workshops, educational outreach visits, written educational material, audit and feedback, telephone calls, electronic prompts or reminders, list of at-risk patients, patient risk assessment) **specific to osteoporosis** (not a component of a general intervention on chronic diseases)?

    □ Yes
    □ No → *Exclude study*
    □ Unclear

STUDY DESIGN

2. This study is :

    □ A patient-randomized controlled trial
    □ A cluster-randomized controlled trial
    □ A controlled clinical trial or a quasi-randomized trial
    □ A controlled before-after (pre-post) study
    □ An interrupted time-series
    □ None of the above → *Exclude study*

CONTINUED →

TYPE OF PARTICIPANTS

3. Which health professionals are targeted by the intervention? (you may check more than one option):

   - ☐ Primary care physicians
   - ☐ Patients
   - ☐ Primary care nurses
   - ☐ Community pharmacists
   - ☐ Primary care physicians and medical specialists (e.g. orthopedic surgeons)
   - ☐ None of the above, please specify: _____ → *Exclude study*
   - ☐ Unclear

4. What is the study population for the evaluation of the osteoporosis-related outcomes (e.g. fractures, BMD tests)?

   - ☐ Patients at risk of fracture
   - ☐ Patients at high-risk of fracture
   - ☐ Patients at risk and patients at high risk of fracture
   - ☐ None of the above, please specify: _____ → *Exclude study*
   - ☐ Unclear

5. What is the osteoporosis status of the patients included in this study?

   - ☐ Patients at risk candidate for osteoporosis screening (without previous BMD testing and without osteoporosis treatment)
   - ☐ Patients at high risk candidate for osteoporosis treatment (without osteoporosis treatment with a bisphosphonate)
   - ☐ Patients at risk and patients at high risk candidate for osteoporosis screening or treatment (without previous BMD testing and without osteoporosis treatment)
   - ☐ None of the above, please specify: _____ → *Exclude study*
   - ☐ Unclear

DURATION OF PATIENT'S FOLLOW-UP

6. What is the duration of the patient's follow-up after the intervention?

   - ☐ 3 months or more, please specify: _____
   - ☐ Less than 3 months → *Exclude study*
   - ☐ Unclear

TYPE OF COMPARATOR

7. What is the comparative intervention?

   - ☐ Usual care (or no intervention)
   - ☐ Intervention targeting a health problem other than osteoporosis, please specify: _____
   - ☐ None of the above, please specify: _____ → *Exclude study*
   - ☐ Unclear

Eligibility evaluation form - Guide

STUDY DESIGN (Question 2)

- **Randomized controlled trials (RCTs)** are trials in which the participants (or other units) are assigned prospectively to study groups using a process of random allocation (e.g. random number generation, coin flip).
- **Controlled clinical trials (CCTs)** are defined as trials in which participants (or other units) are either:
    a) assigned prospectively to study groups using a quasi-random allocation method (e.g. alternation, date of birth, patient identifier) or
    b) *possibly* assigned prospectively using a process of random or quasi-random allocation.
- **Controlled before-after (CBA) studies (or controlled pre-post studies)** are defined as studies in which observations are made before and after the implementation of an intervention, both in a group that receives the intervention and in a comparable control group that does not. In order to be included as a CBA analysis, the study must fulfill the following 2 criteria:
    - *Have a contemporaneous data collection* : If pre and post intervention periods for study and control sites are the same
    - *Have an appropriate choice of control site* : If study and control sites are comparable with respect to dominant reimbursement system, level of care, setting of care and academic status
- **Interrupted time-series (ITS) studies** are defined as studies reporting outcomes in at least 3 time points in the pre-intervention period and in at least 3 time points in the post-intervention period. In order to be included as a ITS analysis, the study must fulfill the following 2 criteria:
    - *Have a clearly defined point in time when the intervention occurred* : If reported that the intervention occurred at a clearly defined point in time
    - *Have at least 3 data points before and 3 after the intervention* : If 3 or more data points are recorded before and 3 or more data points are recorded after the intervention.

TYPE OF PARTICIPANTS

Question 3 : Include study if the intervention involves medical specialists (e.g. rheumatologists, orthopedic surgeon) but a component of the intervention involves primary care physicians.

Question 4 :

- Score "Patients **<u>at risk</u>** for fracture" if the intervention is assessed in :
    - Women aged ≥65 years;
    - Men aged ≥70 years;

      or

    - Men or women aged ≥50 years with at least one major risk factor for osteoporosis (family history of osteoporosis, malabsorption syndrome, primary hyperparathyroidism, hypogonadism, or early menopause).

- Score "Patients **<u>at high risk</u>** for fracture" if the intervention is assessed in :
    - Men or women of any age with a previous fragility fracture (hip, wrist or spine);

      or

    - Men or women of any age receiving glucocorticoids at a daily dose of >7.5 mg prednisone or equivalent for more than 3 months.

Question 5 : Bisphosphonates include alendronate, risedronate and etidronate.

Question 7 : A comparison group receiving usual care as well as printed material on osteoporosis will be considered as an "usual care" group.